Clinical Trial Update: Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial update for vorasidenib (S095032/AG-881) in Asian participants with residual or recurrent Grade 2 IDH-mutant glioma; study status is ACTIVE_NOT_REC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Glioma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: Servier | Conditions: Residual or Recurrent Grade 2 IDH Mutant Glioma | Phase 3 | Status: ACTIVE_NOT_RECRUITING